Mirum says brelovitug hits primary endpoint in Phase 3 AZURE-4 trial for hepatitis deltaNov 10Clinical readoutbulevirtideMirum Pharmaceuticals, Inc.
Mirum reports four positive readouts, raises 2026 sales guidance to $715M-$720MNov 3Quarterly updatebulevirtidemaralixibat
Mirum reports positive Cohort 2 data for ATEBRIOZ in younger FOP patientsOct 26Regulatory decisionMirum Pharmaceuticals, Inc.
Mirum reports positive Phase 3 EXPAND data for Livmarli in cholestatic liver diseasesOct 13Clinical readoutmaralixibatMirum Pharmaceuticals, Inc.
FDA approves Mirum and Incyte's Atebrioz for FOP; brelovitug hits Phase 3 HDV endpointSep 28Regulatory decisionbulevirtideMirum Pharmaceuticals, Inc.
Mirum registers Phase 2 trial of maralixibat for cholestasis of pregnancySep 16Trial updatemaralixibatMirum Pharmaceuticals, Inc.
Mirum raises 2026 sales guidance, volixibat gets FDA breakthrough status for PSCAug 5Quarterly updateMirum Pharmaceuticals, Inc.volixibat
Mirum registers Phase 1 ADME trial for MRM-3379 in healthy male volunteersJul 17Trial updateMirum Pharmaceuticals, Inc.MRM-3379